GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Eisai and Biogen are one step away from deploying a more convenient version of their jointly developed Alzheimer’s treatment ...

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...

The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

Leqembi is not known to interact with alcohol, other drugs, or supplements. However, the drug has some health-related interactions. Talk with your doctor to avoid potentially harmful effects from ...

Biogen CEO Chris Viehbacher targets subcutaneous Leqembi release for Alzheimers treatment Biogens Chris Viehbacher outlines ...

To date, Leqembi has been approved in the US, Japan, China, South Korea, Hong Kong, Israel, UAE, GB, Mexico, and Macau, and ...

As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...

( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...

The FDA accepted Biogen and Eisai’s BLA for a subcutaneous administration of the anti-amyloid antibody Monday as the partners await the regulator’s decision on a new intravenous regimen following an ...

However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of catalysts” that could accelerate Leqembi’s growth in 2025. Since its approval in 2023, the launch of the ...